An exciting announcement by IRIDEX Corporation about a scientific research outcome contrasting outcomes attained in treating DME (diabetic macular edema) employing IRIDEX MicroPulse Laser against those acquired by the established benchmark care ETDRS laser procedure.
By the conclusion of a year’s time, IRIDEX MicroPulse procedure had analogous efficacy like the ETDRS (Early Treatment of Diabetic Retinopathy Study) in treating DME. Furthermore, retinal sensitiveness in eyes among the IRIDEX treatment set showed improvement. In the ETDRS set, there was a decrease in retinal sensitiveness. There were no noticeable indicators of laser harm to tissues of the retina among the IRIDEX set while people from the ETDRS set were observed to develop localization of laser scarring.
This pioneering laser study finding illustrates a major enhancement in core visual functioning in comparison to benchmark ETDRS laser photo-coagulation therapy of diabetic macular edema. Such research outcomes are vital to IRIDEX Corporation since they were accomplished employing IRIDEX laser and MicroPulse Treatment and DME is among the commonly conducted retinal laser methods.
Moreover, obtaining the well-known invariable advantages of laser photo coagulation employing tissue-sparing strategy that would not cause harm to tissues despite re-treatments, might pave the way for a re-evaluation of a person’s therapy measure and eventually to enhanced ocular results among unremitting diabetes cases.
Italian research conducted at the Univ. of Padova did a prospective randomization by enrolling sixty-two eyes with medically critical DME. Study entrants underwent a yearlong treatment with ETDRS photo coagulation procedure (argon laser photo coagulator assisted) or with MicroPulse sub-threshold therapy procedure (IRIDEX Oculight SLx laser photocoagulator assisted). At the conclusion of these duo therapies, both sets exhibited a noteworthy improvement in core retinal thickness size and stabilized optical sharpness. Although no major variation was noted in both the above factors in-between the sets but a major variation was noted in retinal sensitiveness measurement observed to improve in the MicroPulse set and diminish in the ETDRS set.
Study authors noted that enhancement in retinal sensitiveness, a sign of enhanced core optical functioning that generally corresponds to an individual’s personal discernment of their broad vision quality, encourages the usage of sub threshold MicroPulse laser, a lesser belligerent curative choice in treating DME.
MicroPulse is a tissue-sparing laser deliverance sentiency which functions by electronic hacking of laser emitted into trains of micro-second pulsations. This brings about an improvement in a doctor’s capability of more accurately controlling laser outcomes on targeted tissues which offers a promise of visual therapy having analogous or more expediency with lesser collateral outcomes as compared to traditional laser therapies.
